Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADUS Addus HomeCare	$113.86 -2.1%	$111.87	$88.96 ▼ $136.72	$2.14B	0.8	195,814 shs	192,027 shs
FTRE Fortrea	$7.90 +0.8%	$5.71	$3.97 ▼ $25.28	$711.87M	1.81	2.00 million shs	1.46 million shs
PGNY Progyny	$22.55 -2.2%	$22.38	$13.39 ▼ $26.76	$1.98B	1.32	1.13 million shs	1.05 million shs
VCYT Veracyte	$30.04 -2.1%	$26.29	$22.61 ▼ $47.32	$2.41B	1.97	2.45 million shs	1.39 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADUS Addus HomeCare	-2.12%	+4.36%	+4.05%	+2.00%	-11.07%
FTRE Fortrea	+0.77%	+9.12%	+67.37%	+77.93%	-65.95%
PGNY Progyny	-2.21%	-2.21%	-2.97%	+1.12%	+10.00%
VCYT Veracyte	-2.09%	+8.53%	+19.02%	+2.88%	-3.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADUS Addus HomeCare	4.9449 of 5 stars	3.6	3.0	5.0	3.8	2.5	3.1
FTRE Fortrea	3.8431 of 5 stars	4.1	3.0	0.0	2.7	1.7	1.9
PGNY Progyny	2.1108 of 5 stars	2.4	2.0	0.0	2.5	2.5	1.3
VCYT Veracyte	2.5395 of 5 stars	3.4	0.0	4.3	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADUS Addus HomeCare	3.25	Buy	$142.86	25.47% Upside
FTRE Fortrea	2.15	Hold	$13.30	68.35% Upside
PGNY Progyny	2.73	Moderate Buy	$24.90	10.42% Upside
VCYT Veracyte	2.70	Moderate Buy	$40.90	36.15% Upside

Current Analyst Ratings Breakdown

Latest FTRE, VCYT, ADUS, and PGNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underweight ➝ Underweight	$28.00
8/8/2025	PGNY Progyny	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$28.00
8/8/2025	FTRE Fortrea	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	In-Line ➝ In-Line	$5.00 ➝ $7.00
8/8/2025	PGNY Progyny	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$26.00 ➝ $28.00
8/7/2025	FTRE Fortrea	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight	$5.00 ➝ $6.00
8/6/2025	ADUS Addus HomeCare	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$135.00 ➝ $139.00
8/4/2025	FTRE Fortrea	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2025	FTRE Fortrea	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$7.00 ➝ $9.00
7/17/2025	PGNY Progyny	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$24.00 ➝ $27.00
7/16/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
7/11/2025	FTRE Fortrea	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$8.00 ➝ $7.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADUS Addus HomeCare	$1.15B	1.82	$5.28 per share	21.58	$55.51 per share	2.05
FTRE Fortrea	$2.70B	0.27	$1.58 per share	4.99	$6.49 per share	1.22
PGNY Progyny	$1.17B	1.66	$0.34 per share	66.82	$5.99 per share	3.76
VCYT Veracyte	$445.76M	5.30	$1.02 per share	29.59	$15.52 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADUS Addus HomeCare	$73.60M	$4.53	25.13	21.24	1.77	6.51%	9.39%	6.86%	11/3/2025 (Estimated)
FTRE Fortrea	-$328.50M	-$11.38	N/A	6.17	N/A	-37.57%	5.25%	1.72%	N/A
PGNY Progyny	$54.34M	$0.59	38.22	34.69	2.25	4.28%	10.69%	7.12%	N/A
VCYT Veracyte	$24.14M	$0.33	91.03	41.72	N/A	5.50%	6.07%	5.53%	N/A

Latest FTRE, VCYT, ADUS, and PGNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PGNY Progyny	$0.42	$0.19	-$0.23	$0.19	$315.70 million	$332.87 million
8/6/2025	Q2 2025	FTRE Fortrea	$0.06	$0.19	+$0.13	-$4.14	$631.61 million	$710.30 million
8/4/2025	Q2 2025	ADUS Addus HomeCare	$1.45	$1.49	+$0.04	$1.20	$345.71 million	$349.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADUS Addus HomeCare	N/A	N/A	N/A	N/A	N/A
FTRE Fortrea	N/A	N/A	N/A	N/A	N/A
PGNY Progyny	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADUS Addus HomeCare	0.17	1.74	1.74
FTRE Fortrea	1.87	1.02	1.02
PGNY Progyny	N/A	2.70	2.39
VCYT Veracyte	N/A	5.43	5.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADUS Addus HomeCare	95.35%
FTRE Fortrea	N/A
PGNY Progyny	94.93%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ADUS Addus HomeCare	4.50%
FTRE Fortrea	0.38%
PGNY Progyny	9.40%
VCYT Veracyte	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADUS Addus HomeCare	49,703	18.41 million	17.58 million	Optionable
FTRE Fortrea	15,500	90.80 million	90.46 million	Optionable
PGNY Progyny	310	85.98 million	77.90 million	Optionable
VCYT Veracyte	790	78.67 million	77.57 million	Optionable

FTRE, VCYT, ADUS, and PGNY Headlines

Recent News About These Companies

Veracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Average PT from Analysts

1 hour ago | americanbankingnews.com

Connor Clark & Lunn Investment Management Ltd. Decreases Holdings in Veracyte, Inc. (NASDAQ:VCYT)

August 13 at 4:36 AM | marketbeat.com

VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

August 12 at 9:26 AM | zacks.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from Analysts

August 12 at 2:43 AM | marketbeat.com

Veracyte (NASDAQ:VCYT) Stock Price Up 12.5% - Should You Buy?

August 8, 2025 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript

August 8, 2025 | msn.com

Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight

August 7, 2025 | gurufocus.com

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Veracyte, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 7, 2025 | seekingalpha.com

Veracyte (VCYT) Q2 Revenue Jumps 14%

August 7, 2025 | fool.com

Veracyte shares surge as Q2 profits quadruple expectations

August 6, 2025 | in.investing.com

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

August 6, 2025 | zacks.com

Veracyte Inc (VCYT) Q2 2025 Earnings: Revenue Surpasses Estimates at $130.2M, Reports GAAP Net Loss

August 6, 2025 | gurufocus.com

Veracyte Announces Second Quarter 2025 Financial Results

August 6, 2025 | businesswire.com

Veracyte Inc (VCYT) Q2 2025 Earnings Report Preview: What to Look For

August 6, 2025 | finance.yahoo.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Position in Veracyte, Inc. (NASDAQ:VCYT)

August 6, 2025 | marketbeat.com

Federated Hermes Inc. Has $2.80 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)

August 5, 2025 | marketbeat.com

GSA Capital Partners LLP Takes Position in Veracyte, Inc. (NASDAQ:VCYT)

August 1, 2025 | marketbeat.com

Picton Mahoney Asset Management Has $7.72 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)

July 30, 2025 | marketbeat.com

Veracyte (VCYT) to Release Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

Victory Capital Management Inc. Purchases 41,248 Shares of Veracyte, Inc. (NASDAQ:VCYT)

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTRE, VCYT, ADUS, and PGNY Company Descriptions

Addus HomeCare NASDAQ:ADUS

$113.86 -2.47 (-2.12%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$113.88 +0.02 (+0.01%)

As of 08/14/2025 07:57 PM Eastern

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Fortrea NASDAQ:FTRE

$7.90 +0.06 (+0.77%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.91 +0.01 (+0.13%)

As of 08/14/2025 07:55 PM Eastern

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Progyny NASDAQ:PGNY

$22.55 -0.51 (-2.21%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$22.54 -0.02 (-0.07%)

As of 08/14/2025 05:15 PM Eastern

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Veracyte NASDAQ:VCYT

$30.04 -0.64 (-2.09%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$30.20 +0.16 (+0.53%)

As of 08/14/2025 05:29 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time